The Sino foreign joint venture version of GSK case Guangzhou Baite Qiaoguang was exposed to make up the conference fee

Original title [the Sino foreign joint venture version of GSK case Guangzhou Baite Qiaoguang is exposed to make up the conference fee] After many foreign pharmaceutical companies have been investigated, domestic enterprises are also involved in the storm On August 2, the Wall Street Journal revealed that Guangzhou Baite Qiaoguang medical supplies Co., Ltd., a joint venture of American Baite company and Guangzhou Pharmaceutical (600332) group, conspired with travel agencies to draw meeting funds for bribery of government officials in exchange for product concessions through fictitious meetings and other means A spokesman for Baite news said the Chinese government had not contacted the company and did not know whether China had launched an investigation On August 5, the phone call of the head of public relations of Baite company remained unanswered Guangyao group issued a statement on the official website on August 2, saying: "China deeply regrets that Baite Qiaoguang has violated the regulations In the previous board of directors, China has severely condemned this behavior!" According to the Wall Street Journal, the whistleblowers reported the situation to Baite in July 2012 Baite failed to confirm the content of the report after investigation, but found some "illegal spending behaviors" Therefore, in July 2013, the whistleblower directly disclosed to the media about setting up a conference and drawing money for bribery According to the information disclosed, Guangzhou Baite Qiaoguang carried out an internal investigation in July 2012 and punished the leadership of Baite Qiaoguang, but this incident has not been disclosed "Baite Qiaoguang's fat emulsion injection is not particularly advantageous If the disclosure is true, the rapid growth of sales in recent years may be related to the content of the disclosure," a person from the marketing department of a pharmaceutical industry in Sichuan said Working together "With the resources of Guangyao group It shows that the price of clinol is reasonable and can be "priced separately" into Fujian Medical Insurance catalogue After the exposure of the incident, Guangyao group quickly issued a statement that "the daily operation of Baxter Qiaoguang is dominated by Baxter, and the business management mode is also built according to the structure of Baxter" The head of Guangyao group also disclosed through other media that "Guangyao is only responsible for the production and scientific research of Baite Qiaoguang" Our reporter learned that the relationship between Baite and Guangyao group is not dominated by Baite, but the two sides work together Especially when it comes to government affairs On November 24, 2010, the medium / long chain fat emulsion injection of Baite Qiaoguang obtained the qualification of differential pricing of drugs in Guangdong Province, according to a promotional manuscript published on the official website of Guangzhou Pharmaceutical Group "In this application for differential pricing, both shareholders of Baite Qiaoguang: Guangyao group, Baiyunshan Co., Ltd and Baite have attached great importance to it, and provided strong support for the application work A project team led by the government affairs department and participated by finance, R & D, quality and other departments has been specially established " Fat emulsion injection is a nutritional drug, the above-mentioned pharmaceutical industry insiders said: "in the case of patients unable to eat after surgery, it is difficult to ensure the nutritional balance by simply infusion of glucose, so it is OK to use medium and long chain fat emulsion In theory, the longer the chain, the better " In another publicity release on January 24, 2013, the imported product "Clino" sold by Baite Qiaoguang failed to obtain the qualification of independent pricing in the medical insurance bidding of Fujian Province in 2012 Although Baite Qiaoguang started the government public relations plan at the beginning of last year, the result was still unsatisfactory Finally, "with the help of the resources of Guangyao group, through Fujian Guangyao Jieda Pharmaceutical Co., Ltd., and through continuous communication with the medical insurance Department of the human resources and Social Security Department of Fujian Province, to explain the rationality of clinol's price", we were able to enter the Fujian Medical Insurance catalogue with "separate pricing", and get rid of the fate of being pressed to win the bid Under the "action plan" of the government affairs department of Baxter Qiaoguang, the "clinol" produced by Baxter entered the supplementary catalogue of medical insurance in Guangdong, Hainan, Tianjin, Chongqing, Gansu, Shanxi, Fujian and other provinces and cities as a separate pricing identity Differential pricing and separate pricing mean that the medical insurance can be entered at a price higher than that of similar drugs, which is of great significance to enterprises According to the report, Baite Qiaoguang "bribes Chinese government officials in exchange for the government's granting of product concessions" There is no official information about whether the "support" and "communication" mentioned in the above-mentioned publicity release are related to the incident It has been made clear that since the internal report was received by Baite Qiaoguang in July 2012, the board of directors composed of Baite and Guangyao disciplined the company's leadership, carried out training and strengthened supervision, but did not disclose the incident to the public Since its establishment on August 8, 2007, the company's performance has been unsatisfactory and has been losing money for years However, in 2011, the company realized a turnaround, with a revenue of 211 million yuan and a net profit of 4.7575 million yuan At present, the company's products in Beijing, Shanghai, Guangdong and other 18 provinces and cities won the medical insurance catalog Among them, Heilongjiang, Zhejiang, Guizhou, Hubei and other provinces have different degrees of differential pricing qualifications Baite's low-key gold digging In the Chinese market, Baite focuses on infusion, Nephrology, parenteral nutrition, anesthesia and other fields After the exposure of suspected bribery, Baite did not have a direct response to the report Baite is the world's largest infusion manufacturer In the Chinese market, Baite focuses on infusion, Nephrology, parenteral nutrition, anesthesia and other fields Parenteral nutrition medicine represented by fat emulsion is one of its core businesses Baite Qiaoguang, formerly a subsidiary of Baiyunshan (000522), formerly known as Guangzhou Qiaoguang pharmaceutical, was injected into Baiyunshan when it was reorganized in 2001 In August 2007, the joint venture company Baite Qiaoguang was established, and Baite and Baiyunshan each held 50% of its equity According to the agreement at that time, Baite has the right to increase its holding right to 60% after August 2009 Qiaoguang pharmaceutical's most famous product is medium / long chain fat emulsion injection, which was successfully developed as early as 1992 Baite has higher technology in the field of medium / long chain fat emulsion, and the cooperation between the two sides is just a model of combining technical advantages and market advantages However, the above-mentioned Sichuan Pharmaceutical Enterprise personage said: "the domestic variety started in the late 1980s, and Qiaoguang is not the first With its sales volume of 205 million in 2011, it can only rank in the middle of the industry Technically, every family has its own advantages, and Qiaoguang is not alone " On April 12, 2011, Baite China and Guangyao group agreed that "obtaining the direct sales right of Baite European products such as olive oil fat emulsion injection (clinol)" is the biggest opportunity After cooperation, "Clino" was able to enter 8 provinces and cities Baite's government public relations strength is not weak Baite International Co., Ltd announced through its subsidiary in China that Baite signed a memorandum of understanding with the former Hospital Management Research Institute of the Ministry of health of China on November 6, 2012 The two sides will cooperate to develop and promote sustainable peritoneal dialysis treatment and distribution mode for patients with end-stage renal disease living in rural areas The content of cooperation involves increasing the proportion of peritoneal dialysis guaranteed by medical insurance and new rural cooperative fund Peritoneal dialysis is a more effective treatment than hemodialysis Baite is the leader of peritoneal dialysis technology, occupying more than 70% of the global market At present, Gansu, Jiangsu Lianyungang and other provinces and cities have clearly promoted this technology to treat renal failure and uremia within their jurisdiction Baite's products are likely to enter more grassroots rural markets.